What is Isoformix?
Isoformix is dedicated to the development of innovative assays for protein isoforms, with a particular emphasis on apolipoproteins and their critical role in Alzheimer's disease. The company provides a suite of services designed to propel research forward in this vital area of health. Isoformix aims to serve researchers and organizations actively engaged in Alzheimer's disease studies and related scientific endeavors, offering novel targets and solutions to deepen the understanding and improve the treatment of neurodegenerative conditions.
How much funding has Isoformix raised?
Isoformix has raised a total of $24K across 1 funding round:
Debt
$24K
Debt (2021): $24K with participation from PPP
What's next for Isoformix?
With the recent influx of substantial expansion capital, Isoformix is poised to accelerate its research and development initiatives. The company's strategic focus on protein isoforms and their link to Alzheimer's disease suggests a future emphasis on scaling its assay development capabilities and potentially forging new partnerships within the pharmaceutical and research sectors. This financing is expected to fuel further innovation, enabling Isoformix to solidify its position as a key contributor to neurodegenerative disease research and the broader biotechnology landscape.
See full Isoformix company page